Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study
Table 2
Results showing relationship between baseline characteristics and viral load re-suppression among study participants.
Variables
Viral load
value
Suppressed (n = 156) (%)
Nonsuppressed (n = 79) (%)
Age
<10
6 (3.9)
3 (3.8)
≤0.001
10–19
26 (16.7)
3 (3.8)
20–29
28 (18.0)
25 (31.7)
30–39
32 (20.4)
28 (35.4)
≥40
64 (41.0)
20 (25.3)
Sex
Male
63 (53.2)
51 (51.8)
≤0.001
Female
93 (46.8)
28 (48.2)
Marital status
Single
45 (29.6)
20 (24.1)
0.120
Married
70 (46.1)
39 (47.0)
Widowed
12 (7.9)
12 (14.5)
Divorce
25 (16.4)
12 (14.4)
Educational status
Cannot read and write
57 (37.5)
39 (47.0)
0.03
Primary
65 (42.8)
30 (36.1)
Secondary and above
24 (15.8)
13 (15.7)
Residence
Urban
65 (42.8)
34 (41.0)
<0.001
Rural
87 (57.2)
49 (59.0)
Type of hospital
General hospital
103 (67.8)
54 (65.1)
0.412
Primary hospital
49 (32.2)
29 (34.9)
ART regimen
NVP-based regimen
40 (26.9)
23 (27.7)
0.571
EFV-based regimen
111 (73.1)
57 (72.3)
Duration of ART
≤12 months
42 (26.9)
18 (22.8)
0.037
13–35 months
26 (16.7)
22 (27.9)
36–59 months
72 (46.2)
36 (45.6)
≥60 months
16 (10.3)
3 (3.8)
First viral load
1000–5000
79 (50.6)
26 (32.9)
0.011
5001–10,000
65 (41.7)
25 (31.6)
≥10000
12 (7.7)
28 (35.4)
Baseline CD4
<200
53 (34.0)
40 (50.6)
0.641
201–500
25 (16.0)
17 (21.5)
≥500
78 (50.0)
22 (27.9)
Adherence level
Good
139 (91.5)
56 (67.5)
0.210
Fair
3 (2.0)
7 (8.4)
Poor
10 (6.5)
20 (24.1)
WHO stage
Stage 1
139 (91.5)
74 (89.2)
0.012
Stage 2 or 3
13 (8.6)
7 (8.4)
ART = antiretroviral therapy; EFV = efavirenz; NVP=nevirapine; WHO = World Health Organization.
